We are live on ! Find out more
PASG icon

Passage Bio
PASG

44 hedge funds and large institutions have $21.6M invested in Passage Bio in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

0% more funds holding

Funds holding: 44 → 44 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

0.08% less ownership

Funds ownership: 3.13% → 3.05% (-0.08%)

20% less capital invested

Capital invested by funds: $27.1M → $21.6M (-$5.49M)

Holders
44
Holders Change
–
Holders Change %
0%
% of All Funds
0.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
10
Reduced
9
Closed
9
Calls
$9K
Puts
–
Net Calls
+$9K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
+$541K
2
Morgan Stanley
Morgan Stanley
New York
+$520K
3
SC
Shay Capital
New York
+$86.6K
4
Jane Street
Jane Street
New York
+$42.9K
5
TRCT
Tower Research Capital (TRC)
New York
+$32.2K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$1.57M
2
Citadel Advisors
Citadel Advisors
Florida
-$282K
3
LCM
Landscape Capital Management
New Jersey
-$37.7K
4
Two Sigma Investments
Two Sigma Investments
New York
-$31.7K
5
EGM
Engineers Gate Manager
New York
-$24.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
GSC
26
Ground Swell Capital
South Carolina
$14.4K +$16.6K +1,271 New
Fidelity Investments
27
Fidelity Investments
Massachusetts
$11.9K -$1.17K -90 -8%
HighTower Advisors
28
HighTower Advisors
Illinois
$8.8K -$560 -43 -5%
Barclays
29
Barclays
United Kingdom
$7.46K – – –
HF
30
HRT Financial
New York
$7K +$9.03K +693 New
VF
31
Virtu Financial
New York
$6K +$6.69K +514 New
AWS
32
Atria Wealth Solutions
New York
$5.67K +$6.51K +500 New
MCM
33
MAI Capital Management
Ohio
$2.27K +$2.6K +200 New
SS
34
SBI Securities
Japan
$1.34K +$1.54K +118 New
Osaic Holdings
35
Osaic Holdings
Arizona
$1.01K – – –
Bank of America
36
Bank of America
North Carolina
$239 – – –
JP Morgan Chase
37
JP Morgan Chase
New York
$155 – – –
LI
38
LRI Investments
Florida
$128 – – –
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$105 +$117 +9 New
HI
40
Harbour Investments
Wisconsin
$34 – – –
FFA
41
Farther Finance Advisors
California
$28 +$39 +3 New
Group One Trading
42
Group One Trading
Illinois
$27 – – –
UBS Group
43
UBS Group
Switzerland
$1 – – –
Citadel Advisors
44
Citadel Advisors
Florida
– -$282K -20,126 Closed
LCM
45
Landscape Capital Management
New Jersey
– -$37.7K -2,696 Closed
EGM
46
Engineers Gate Manager
New York
– -$24.3K -1,739 Closed
XT
47
XTX Topco
Cayman Islands
– -$20.7K -1,480 Closed
CAM
48
Cresset Asset Management
Illinois
– -$16.6K -1,186 Closed
TSS
49
Two Sigma Securities
New York
– -$15.1K -1,082 Closed
NA
50
Nordwand Advisors
Pennsylvania
– -$1.75K -125 Closed
1
2
3

PASG Hedge Fund Activity: Q4 2024 in Review

44 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q4 2024, worth a combined $21.6M — down 20% from $27.1M a quarter earlier.

Fund positioning in PASG was balanced in Q4 2024: 9 funds opened new positions, 9 closed out, 10 added to existing stakes and 9 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $541K. The largest seller was OrbiMed, cutting an estimated $1.57M.

  • 44 institutional investors held Passage Bio (PASG) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $21.6M of Passage Bio stock for Q4 2024, down 20% quarter-over-quarter.
  • 9 funds opened new Passage Bio positions in Q4 2024 and 9 closed out, a net change of 0 holders.
  • The largest Passage Bio buyer in Q4 2024 was Lynx1 Capital Management, an estimated $541K added.
  • The largest Passage Bio seller in Q4 2024 was OrbiMed, an estimated $1.57M sold.

Based on aggregated 13F filings for Q4 2024.